(Q54517330)

30 May 2018

title

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. (English)

1 reference

30 May 2018

1 reference

acute myeloid leukemia

1 reference

S K Metzelder

1

1 reference

30 May 2018

T Schroeder

2

1 reference

30 May 2018

A Finck

3

1 reference

30 May 2018

S Scholl

4

1 reference

30 May 2018

M Fey

5

1 reference

30 May 2018

K Götze

6

1 reference

30 May 2018

Y C Linn

7

1 reference

30 May 2018

M Kröger

8

1 reference

30 May 2018

A Reiter

9

1 reference

30 May 2018

H R Salih

10

1 reference

30 May 2018

T Heinicke

11

1 reference

30 May 2018

R Stuhlmann

12

1 reference

30 May 2018

L Müller

13

1 reference

30 May 2018

A Giagounidis

14

1 reference

30 May 2018

R G Meyer

15

1 reference

30 May 2018

W Brugger

16

1 reference

30 May 2018

M Vöhringer

17

1 reference

30 May 2018

P Dreger

18

1 reference

30 May 2018

M Mori

19

1 reference

30 May 2018

N Basara

20

1 reference

30 May 2018

K Schäfer-Eckart

21

1 reference

30 May 2018

B Schultheis

22

1 reference

30 May 2018

C Baldus

23

1 reference

30 May 2018

A Neubauer

24

1 reference

30 May 2018

A Burchert

25

1 reference

30 May 2018

publication date

16 April 2012

1 reference

30 May 2018

published in

Leukemia

1 reference

30 May 2018

volume

26

1 reference

30 May 2018

issue

11

1 reference

30 May 2018

page(s)

2353-2359

1 reference

30 May 2018

https://scigraph.springernature.com/pub.10.1038/leu.2012.105

exact match

0 references

cites work

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

FLT3 as a therapeutic target in AML: still challenging after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

7 January 2021

Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

7 January 2021

Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

7 January 2021

Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.105

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.105

1 reference

30 May 2018

PubMed ID

22504140

1 reference

30 May 2018